ITOC5 – 2018

ITOC5-Banner-728x90-052017-v2

The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) had the great pleasure to welcoming you to the 5th Immunotherapy of Cancer Conference (ITOC5) – the leading international conference providing a global platform in Europe for translational research in the field of immuno-oncology.

The fifth edition (ITOC5) took place on Berlin, Germany, from 19 to 21 March 2018, aiming at providing a forum for all professionals working in immunotherapy to discuss early clinical drug development and address the unique challenges of translational research.

ITOC5 particularly addressed preclinical and clinical scientists, clinical investigators, postdoctoral fellows involved in cancer research, regulatory scientists, healthcare professionals and the pharmaceutical industry.

The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) has the great pleasure to invite you to take part in the 5th Immunotherapy of Cancer Conference (ITOC5) – the leading International conference in Europe providing a global platform for translational research in the field of immuno-oncology. Chairman Heinz Zwierzina (Innsbruck University, Austria) CDDF Headquarters Marjorie Recorbet – Association Manager c/o ECCO, The European Cancer Organisation Avenue E. Mounier 83 1200 Brussels – Belgium Phone: +32.2.775.02.15 Email: cddf@ecco-org.eu Vienna Medical Academy Catherine Tomek E-mail: itoc@medacad.org Telephone: +43 1 405 13 83 18 Rose International Flora van Laer E-mail: fvanlaer@rose-international.com Telephone: +31 70 383 89 01

Have a look at the conference pictures: Google photos

ABSTRACTS

5th Immunotherapy of Cancer Conference (ITOC5), 19-21 March 2018, Berlin, Germany – Abstract Book
European Journal of Cancer (EJC), Volume 92, Supplement 1, S1-S26, March 2018

ACKNOWLEDGEMENT

The ITOC5 Organising Committee wishes to gratefully acknowledge the Scientific Committee and the sponsors for supporting the 5th Immunotherapy of Cancer Conference.

CME CREDITS

The conference has been granted 15 European CME credits by the European Accreditation Council for Continuing Medical Education (EACCME).

LIFETIME ACHIEVEMENT AWARD

The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) has the great pleasure to invite you to take part in the 5th Immunotherapy of Cancer Conference (ITOC5) – the leading International conference in Europe providing a global platform for translational research in the field of immuno-oncology. Chairman Heinz Zwierzina (Innsbruck University, Austria) CDDF Headquarters Marjorie Recorbet – Association Manager c/o ECCO, The European Cancer Organisation Avenue E. Mounier 83 1200 Brussels – Belgium Phone: +32.2.775.02.15 Email: cddf@ecco-org.eu Vienna Medical Academy Catherine Tomek E-mail: itoc@medacad.org Telephone: +43 1 405 13 83 18 Rose International Flora van Laer E-mail: fvanlaer@rose-international.com Telephone: +31 70 383 89 01

A lifetime achievement award has been assigned to Carl H. June, M.D. (Abramson Cancer Center at the University of Pennsylvania, USA) for Personal Commitment and Professional Dedication to Cart T-Cell Therapy for Treatment of Cancer.

PICTURES

Have a look at the conference pictures: Google Photos

POSTER AWARDS

CDDF wishes to congratulate the four winners of the ITOC5 poster awards (awards kindly sponsored by the Munich Tumor Center)

D0197462____ITOC 5 CONFERENCE Berlin ©Michael Hoetzel DGPh
First prize
: Katja Ursic from the Institute of Oncology Ljubljana, Slovenia for the poster Peritumoral gene electrotransfer of interleukin-12 as an adjuvant immunotherapy to intratumoral electrochemotherapy for murine melanoma treatment

 Second prize: Julia Rühl from the Institute of Experimental Immunology, Zürich, Switzerland for the poster Eliciting protective T cell immunity against EBV-associated malignancies by vaccination

Third prize 1: Stephanie McArdle from the The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom for the poster Novel PAP-derived vaccine for the treatment of advanced prostate cancer

Third prize 2: Anamarija Markota from the Division of Clinical Pharmacology, University Hospital, Ludwig Maximilian University, Munich, Germany for the poster Cancer cells regulate Interleukin-22 production to promote tumor growth

PRESENTATIONS

To have access to the conference presentations, please contact CDDF headquarters: cddf@ecco-org.eu

SCIENTIFIC PROGRAMME

View or download the ITOC5 final scientific programme

The scientific programme was completed with a “Hot Topic Interactive Experts’ Session on ‘Combinations to Target Immune Excluded and Immune Desert Solid Tumours’, supported by a medical education grant from Roche.

Join the discussion on Twitter by using #ITOC5 !

twitter32x32

The Cancer Drug Development Forum (CDDF) in collaboration with the Society for Immunotherapy of Cancer (SITC) has the great pleasure to invite you to take part in the 5th Immunotherapy of Cancer Conference (ITOC5) – the leading International conference in Europe providing a global platform for translational research in the field of immuno-oncology. Chairman Heinz Zwierzina (Innsbruck University, Austria) CDDF Headquarters Marjorie Recorbet – Association Manager c/o ECCO, The European Cancer Organisation Avenue E. Mounier 83 1200 Brussels – Belgium Phone: +32.2.775.02.15 Email: cddf@ecco-org.eu Vienna Medical Academy Catherine Tomek E-mail: itoc@medacad.org Telephone: +43 1 405 13 83 18 Rose International Flora van Laer E-mail: fvanlaer@rose-international.com Telephone: +31 70 383 89 01

See you next year!

ITOC6